查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2004728

月经治疗市场：2026-2032年全球市场预测（依治疗方法、药物类别、给药途径、通路、应用及最终用户划分）

Dysmenorrhea Treatment Market by Treatment Type, Drug Class, Route Of Administration, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，月经治疗市场价值将达到 85.1 亿美元，到 2026 年将成长至 92.4 亿美元，到 2032 年将达到 158.3 亿美元，复合年增长率为 9.28%。

主要市场统计数据
基准年 2025 85.1亿美元
预计年份：2026年 92.4亿美元
预测年份 2032 158.3亿美元
复合年增长率 (%) 9.28%

引人入胜的引言，阐述了月经的治疗选择、临床重点、病人期望以及影响医疗保健服务的机构因素。

月经仍然是一个普遍存在的临床问题，促使人们自我护理寻求医疗保健服务、加强患者自我护理，并推动治疗和非治疗性介入的多样化。女性和医疗保健专业人员面临着许多选择，包括非处方药、荷尔蒙避孕药、辅助疗法以及日益增加的医疗设备和数位辅助工具。因此，临床实践、药品分销和产品开发领域的相关人员必须携手合作，收集证据、传递讯息并协调获取管道，以满足患者需求和支付方的期望。

以证据为基础，概述了临床、技术和报销方面的变化如何重塑月经的治疗方法和患者照护。

目前，月经治疗正经历多项变革，这些变革影响着治疗方法的研发、临床实践以及病患的行为。其中最显着的变化之一是，非药物疗法与传统药物疗法并存的趋势日益明显。患者和临床医生越来越愿意将针灸、结构化运动方案、营养补充剂和局部热疗纳入治疗计划，这反映出疼痛管理正朝着多方面综合的方向发展。这种整合的驱动力源自于患者对副作用较少的治疗方法的偏好，以及医疗专业人员为存在标准疗法禁忌症的患者寻求辅助治疗方案的需求。

重点分析 2025 年以后的关税政策如何重塑月经治疗药物整个供应链的采购、製造和分销策略。

政策环境的复杂性加剧了月经治疗相关相关人员的困境。特别是，美国将于2025年实施的关税措施，正对整个供应链和成本结构产生连锁反应。这些贸易相关措施影响药物活性成分、用于热疗和神经调节疗法的医疗设备以及某些营养补充剂生产原料的采购和定价。因此，拥有全球供应链的製造商正在重新审视其筹资策略，并加快考虑将生产迁回国内，并寻求替代供应商以减轻关税相关成本波动的影响。

一个综合细分框架，阐明了治疗方法、给药方法、通路、临床应用和最终用户方面的差异，并有助于制定商业化策略。

了解市场区隔对于使产品开发和商业化策略与临床实践和患者偏好相契合至关重要。按治疗方法类型进行分析时，非药理学的处置方法和药物疗法之间存在着明显的二分法。非药物疗法包括针灸、营养补充品、运动疗法和热疗。在营养补充品领域，医疗保健专业人员和消费者会区分草药萃取物、 Omega-3补充剂和维生素补充剂。鑑于这两种途径并存的现实情况，产品开发人员必须清楚地展现差异化的价值提案。药物通常强调可衡量的症状缓解和标准化剂量，而非药物产品则利用其安全性、便利性和患者感知到的健康益处作为其竞争优势。

对美洲、欧洲、中东和非洲以及亚太地区的临床实践、支付方趋势、监管预期和患者偏好进行区域评估。

月经治疗的区域趋势凸显了不同地区的优先事项和法规环境的差异，这些因素影响治疗方案的采纳、证据标准和患者就医途径。在美洲，儘管药物治疗应用广泛，但消费者对非药物辅助治疗的需求也在不断增长，这得益于蓬勃发展的零售药局管道和日益完善的远距远端医疗服务。由于各地区的报销框架和支付方行为各不相同，製造商不得不根据地区调整定价和证据策略。临床实践指南和患者权益倡导组织影响着医生的处方行为，并推动了临床有效的替代疗法（而非传统镇痛药）的快速普及。

对企业环境进行简要分析，重点关注跨国製药公司、学名药生产商、女性健康专家和医疗保健创新公司的角色。

月经市场呈现多元化的格局，既有成熟的製药公司，也有学名药生产商、女性健康专家和医疗创新企业。大型跨国製药公司凭藉其广泛的业务基础以及与支付方和医疗服务提供者建立的稳固关係，大力推广品牌止痛药和避孕产品。同时，学名药生产商则确保在许多市场提供价格亲民的替代选择。此外，女性健康专家在生殖医学和病人参与拥有丰富的专业知识，能够推广差异化的避孕产品并进行有针对性的宣传宣传活动。

产业领导者可采取的策略重点：产生证据、供应链韧性、综合护理伙伴关係和分段商业化。

产业领导者应优先考虑如何将临床证据的产生与便利的分发系统和以病人为中心的参与模式结合。首先，他们需要投资可操作的临床试验和真实世界证据研究，以收集患者报告的结果、功能指标以及与药物和非药物疗法相比的疗效。这些数据对于说服支付方、临床医生和指南委员会至关重要，同时也指南制定吸引患者的有效讯息，帮助他们实际改善日常生活功能。

我们透过透明的混合方法，结合专家访谈、文献整合、监管分析和资料检验验证，确保获得稳健且可操作的见解。

本研究采用混合研究方法，结合质性专家访谈、系统性文献回顾、监理文件分析、二手资讯整合，以获得可靠的见解。主要研究包括对临床医生、药剂师、支付方代表和产品开发经理进行结构化访谈，以检验临床路径、产品应用驱动因素和未满足的需求。二手研究则涉及对已发布的临床指南、同行评审的临床研究、监管指导文件以及公开的企业资讯披露进行审查，以验证研究结论并识别新兴趋势。

以循证差异化、供应链韧性、本地化适应和以患者为中心的护理路径为重点的综合分析得出结论。

这项综合分析凸显了月经治疗领域的一个转捩点：传统药物疗法正与非药物辅助疗法和数位化解决方案相结合，以满足不断变化的患者需求。投资于严谨的实证医学研究、稳健的供应链以及整合式医疗伙伴关係的相关人员将更有利于获得临床和商业性价值。同时，关税和区域政策差异导致的供应链中断，要求积极的风险管理措施和因地制宜的市场策略，以避免供应中断和价格压力。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依治疗方法分類的经痛治疗市场

  • 非药物疗法
    • 针刺
    • 营养补充品
      • 草药萃取物
      • Omega-3补充剂
      • 维生素补充剂
    • 运动疗法
    • 热疗
  • 药物治疗

第九章：月经治疗市场：依药物类别划分

  • 荷尔蒙避孕药
  • NSAIDs

第十章：月经治疗市场：依给药途径划分

  • 注射药物
  • 口服
  • 外用

第十一章：经月经治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：经痛治疗市场：依应用领域划分

  • 原发性经痛
  • 续发性月经

第十三章：月经治疗市场：依最终使用者划分

  • 诊所
  • 居家照护
  • 医院
  • 专业医疗中心
    • 健身中心
    • 妇科诊所

第十四章：经月经治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：经月经治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：经月经治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国月经治疗市场

第十八章：中国经痛月经市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Astellas Pharma
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc（GSK）
  • Haleon Plc
  • Himalaya Wellness Co.
  • Johnson & Johnson
  • Lupin
  • Novartis International AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Reckitt Benckiser Group PLC.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-742BD517DA92

The Dysmenorrhea Treatment Market was valued at USD 8.51 billion in 2025 and is projected to grow to USD 9.24 billion in 2026, with a CAGR of 9.28%, reaching USD 15.83 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.51 billion
Estimated Year [2026] USD 9.24 billion
Forecast Year [2032] USD 15.83 billion
CAGR (%) 9.28%

A compelling introductory framing that situates dysmenorrhea treatment choices, clinical priorities, patient expectations, and systemic forces shaping care delivery

Dysmenorrhea remains a pervasive clinical concern that drives healthcare utilization, consumer self-care, and an expanding mix of therapeutic and non-therapeutic interventions. Women and healthcare providers navigate a complex set of choices that include over-the-counter analgesics, hormonal contraceptives, complementary therapies, and an increasing array of device-based or digital adjuncts. As a result, stakeholders across clinical practice, pharmacy distribution, and product development must coordinate evidence generation, messaging, and access pathways to meet patient needs and payer expectations.

Clinical priorities have shifted toward personalized pain management that balances efficacy, tolerability, reproductive planning, and long-term safety. Patients are more informed and expect treatment pathways that address both acute symptom relief and underlying contributors to recurrent pain. Meanwhile, regulatory agencies and payers are demanding clearer clinical endpoints and real-world effectiveness data to support reimbursement and labeling claims. These forces are converging with broader healthcare trends-such as telehealth, direct-to-consumer distribution, and increased demand for non-pharmacological options-to reshape how dysmenorrhea care is developed, delivered, and scaled.

Consequently, manufacturers, clinicians, and policy stakeholders must align clinical evidence strategies with distribution and patient engagement models. This alignment requires cross-functional planning that integrates clinical trial design, comparative effectiveness research, digital engagement metrics, and supply chain resilience. Taken together, such an integrated approach can improve patient outcomes while creating differentiated market positions for therapies and care models that demonstrate meaningful value beyond symptom suppression.

An evidence-focused overview of the clinical, technological, and reimbursement shifts that are reshaping dysmenorrhea treatment approaches and patient care

The landscape for dysmenorrhea treatment is undergoing several transformative shifts that affect therapeutic development, clinical practice, and patient behavior. One of the most consequential shifts is the mainstreaming of non-pharmacological approaches alongside conventional drug therapies. Patients and clinicians are increasingly open to integrating acupuncture, structured exercise programs, dietary supplements, and targeted heat therapy into care plans, reflecting a broader move toward multimodal pain management. This integration is driven by patient preference for lower side-effect profiles and by practitioners seeking complementary options for those with contraindications to standard therapies.

Concurrently, digital health solutions and wearable technologies are altering the patient experience. Mobile symptom tracking, telemedicine consultations, and digitally enabled adherence tools allow for more nuanced monitoring of treatment response and lifestyle factors. Such capabilities support more individualized therapy adjustments and create opportunities for outcome-based care models. Additionally, innovation in topical formulations and localized delivery systems is enabling faster onset of symptom relief with fewer systemic effects, which appeals to patients prioritizing rapid and targeted outcomes.

Regulatory and reimbursement environments are also shifting, emphasizing real-world evidence and patient-reported outcomes in value assessments. Pharmaceutical and device developers must therefore invest in pragmatic clinical trials and longitudinal outcome studies to demonstrate utility across diverse populations. Taken together, these transformative shifts underscore a market moving from one-size-fits-all approaches toward individualized, evidence-backed care pathways that combine pharmacological and non-pharmacological modalities to meet evolving patient and payer expectations.

A focused analysis of how post-2025 tariff policies have reshaped sourcing, manufacturing, and distribution strategies across dysmenorrhea treatment supply chains

The policy environment has introduced a layer of complexity for stakeholders in dysmenorrhea treatment, particularly as tariff measures enacted in the United States in 2025 have had cascading effects across supply chains and cost structures. These trade-related measures have influenced the sourcing and pricing of active pharmaceutical ingredients, medical devices used for heat therapy and neuromodulation, and certain raw materials for dietary supplement manufacturing. As a result, manufacturers with global supply chains have re-evaluated sourcing strategies, accelerated reshoring considerations, and sought alternative suppliers to mitigate exposure to tariff-related cost volatility.

In practical terms, the cumulative impact has been most visible in procurement and contracting decisions. Healthcare providers and distributors are increasingly prioritizing supplier diversification and entering longer-term agreements to stabilize unit costs. Contract manufacturers have seen heightened demand for cost transparency and tariff pass-through analyses as pharmaceutical firms attempt to preserve affordability for end users without compromising margins. At the same time, companies with vertically integrated supply chains or near-shore manufacturing capabilities have found strategic advantages in maintaining competitive pricing and ensuring continuity of supply.

Policy uncertainty has also incentivized investment in tariff-sensitive risk management, including hedging strategies, inventory buffering, and increased use of free trade agreements where available. For innovators and smaller firms, the added complexity can create barriers to market entry or slow commercialization timelines unless they secure distribution partnerships or localized manufacturing arrangements. Overall, the tariff-driven adjustments underline the importance of evaluating geopolitical and trade policy risks when planning product launches and channel strategies for dysmenorrhea therapies and adjunctive devices.

An integrated segmentation framework that clarifies therapeutic, delivery, channel, clinical application, and end-user distinctions to inform commercialization tactics

Understanding segmentation is essential for aligning product development and commercialization strategies with clinical practice and patient preferences. When treatments are considered by type, there is a clear bifurcation between non-pharmacological and pharmacological approaches; non-pharmacological modalities include acupuncture therapy, dietary supplements, exercise therapy, and heat therapy, and within dietary supplements practitioners and consumers distinguish between herbal extracts, omega-3 supplements, and vitamin supplements. This dual-pathway reality means that product developers must articulate differentiated value propositions: pharmacological agents typically emphasize measurable symptom reduction and standardized dosing, while non-pharmacological offerings compete on safety profile, convenience, and patient-perceived wellness benefits.

Looking at drug class segmentation, hormonal contraceptives and nonsteroidal anti-inflammatory drugs represent two principal therapeutic families, each serving different clinical objectives and patient populations. Hormonal contraceptives are often selected for patients seeking both cycle regulation and long-term control of cramping, whereas NSAIDs remain the frontline choice for acute pain relief due to their established efficacy profile. Route of administration also influences adoption dynamics: injectable, oral, and topical delivery formats create distinct adherence patterns and tolerability considerations that inform prescribing choices and product positioning.

Distribution channels further shape access and patient behavior, with hospital pharmacies, online pharmacies, and community pharmacies each offering unique advantages around immediacy, counseling, and convenience. Application-based segmentation between primary and secondary dysmenorrhea affects clinical pathway design and evidence requirements, while end-user segmentation across clinics, home care, hospitals, and specialty centers-with specialty centers encompassing fitness centers and gynecological clinics-highlights diverse points of care and potential partnership opportunities. Together, these layered segmentation dimensions enable companies to prioritize target populations, tailor messaging, and design evidence-generation programs that align with how therapies will be used in real-world settings.

A regionally differentiated assessment of clinical practice, payer dynamics, regulatory expectations, and patient preferences across the Americas, EMEA, and Asia-Pacific

Regional dynamics in dysmenorrhea treatment reveal differentiated priorities and regulatory contexts that affect adoption, evidence standards, and patient access. In the Americas, there is strong uptake of both pharmacological treatments and a growing consumer demand for complementary non-pharmacological options, supported by robust retail pharmacy channels and expanding telehealth services. Reimbursement frameworks and payer behavior vary by jurisdiction, prompting manufacturers to adapt pricing and evidence strategies regionally. Clinical practice guidelines and patient advocacy influence prescriber habits and rapid adoption of clinically validated alternatives to traditional analgesics.

The Europe, Middle East & Africa region presents a heterogeneous landscape with diverse regulatory regimes and healthcare financing models. In several European markets, higher regulatory scrutiny and established guideline-driven care pathways prioritize high-quality clinical data and long-term safety evidence. Meanwhile, certain markets within the Middle East and Africa emphasize affordability and accessibility, which favors low-cost generics and scalable non-pharmacological interventions. Payer fragmentation and variable diagnostic coding practices require localized market access strategies and partnerships with regional distributors and clinical centers.

In Asia-Pacific, demographic trends, rising healthcare spending, and rapid digital adoption are accelerating demand for a broad spectrum of treatment options, including technologically enabled devices and telehealth-enabled care models. Regulatory harmonization efforts and expanding clinical research infrastructure support faster evidence generation, while culturally specific preferences guide the acceptance of complementary therapies. Across all regions, manufacturers must balance global development plans with tailored local execution to address regulatory requirements, distribution realities, and patient expectations effectively.

A concise corporate landscape analysis that highlights the roles of multinational pharmaceutical firms, generics manufacturers, women's health specialists, and medtech innovators

Corporate behavior across the dysmenorrhea landscape reflects a mix of established pharmaceutical players, generics manufacturers, specialist women's health firms, and medtech innovators. Large multinational drug companies leverage broad commercial footprints and established relationships with payers and providers to support branded analgesics and contraceptive solutions, while generics manufacturers ensure widespread availability of cost-sensitive options in many markets. At the same time, specialized firms focused on women's health bring concentrated expertise in reproductive therapeutics and patient engagement, positioning them to advance differentiated contraceptive formulations and targeted education campaigns.

Medtech and digital health entrants are reshaping the competitive set by introducing device-based pain relief and symptom-tracking platforms that complement pharmacological care. These entrants often pursue partnerships with clinical networks and consumer distribution channels to accelerate adoption and gather real-world usage data. Contract manufacturers and companies with localized production capabilities have become strategically important in the wake of trade and tariff pressures, enabling more predictable supply and improved cost competitiveness. Across the ecosystem, cross-sector collaborations-between pharma, device makers, and digital health providers-are emerging as a primary vehicle for delivering comprehensive, multimodal care pathways that meet the broader needs of patients and providers.

Actionable strategic priorities for industry leaders focused on evidence generation, supply chain resilience, integrated care partnerships, and segmented commercialization

Industry leaders should prioritize initiatives that align clinical evidence generation with accessible distribution and patient-centered engagement models. First, invest in pragmatic clinical trials and real-world evidence studies that capture patient-reported outcomes, functional measures, and comparative effectiveness against both pharmacological and non-pharmacological alternatives. These data will be essential to persuade payers, clinicians, and guideline committees, while also informing messaging that resonates with patients seeking tangible improvements in daily functioning.

Second, diversify supply chains and manufacturing footprints to reduce exposure to tariff and trade policy risk. Near-shoring, multi-sourcing of active ingredients, and deeper collaboration with contract manufacturers can stabilize costs and ensure continuity during geopolitical or policy disruptions. Third, build partnerships across clinical, digital, and retail ecosystems to create integrated care pathways; for example, linking prescribed therapies with digital symptom tracking or heat therapy devices can enhance adherence and provide valuable outcome data.

Finally, tailor go-to-market strategies by combining segmented clinical messaging with channel-specific distribution tactics. For populations prioritizing rapid onset of relief, emphasize topical or fast-acting formulations; for patients focused on long-term control and reproductive planning, highlight hormonal options backed by robust safety data. By executing on these priorities, leaders can accelerate adoption, improve patient satisfaction, and mitigate commercial risks associated with supply chain and policy volatility.

A transparent mixed-methods research approach combining expert interviews, literature synthesis, regulatory analysis, and data triangulation to ensure robust and actionable findings

This study applies a mixed-methods research approach integrating qualitative expert interviews, systematic literature review, regulatory document analysis, and synthesis of secondary public-domain sources to produce robust insights. Primary research includes structured consultations with clinicians, pharmacists, payer representatives, and product development leaders to validate clinical pathways, adoption drivers, and unmet needs. Secondary research canvassed published clinical guidelines, peer-reviewed clinical studies, regulatory guidance documents, and publicly available corporate disclosures to cross-check claims and identify emerging trends.

Data triangulation was used to reconcile differences between stakeholder perspectives and published evidence, and findings were vetted through iterative peer review by subject-matter experts. Segmentation logic was applied across treatment type, drug class, route of administration, distribution channel, clinical application, and end user to ensure that insights map directly to practical commercial and clinical decision points. Limitations include variability in regional data granularity and evolving policy developments that may shift the context after the study's cut-off date; these were mitigated by sensitivity analyses and by capturing a range of expert viewpoints.

Ethical research practices were observed throughout, with all primary interview participants consenting to attribution-free use of insights and confidential information handled under agreed terms. The methodology emphasizes transparency, reproducibility, and pragmatic relevance to inform strategy development and operational planning within the dysmenorrhea treatment ecosystem.

A concluding synthesis that emphasizes evidence-driven differentiation, supply chain resilience, regional adaptation, and patient-centered care pathways

The cumulative analysis underscores an inflection point in dysmenorrhea care where traditional pharmacological strategies are integrating with complementary non-pharmacological modalities and digitally enabled solutions to meet evolving patient needs. Stakeholders who invest in rigorous evidence generation, resilient supply chains, and integrated care partnerships will be best positioned to capture clinical and commercial value. At the same time, tariff-driven supply chain disruptions and heterogeneous regional policies require proactive risk management and localized market strategies to avoid interruption and pricing pressures.

Clinicians and payers alike are increasingly focused on outcomes that matter to patients, including functional improvement and quality-of-life measures, which shifts the burden of proof toward longitudinal and pragmatic evidence rather than short-term symptom metrics alone. For innovators, the path to differentiation lies in demonstrating not only clinical efficacy but also improved daily functioning, safety, and convenience across real-world settings. Ultimately, the most successful approaches will be those that combine rigorous clinical evidence with thoughtful distribution design and patient-centered engagement to deliver sustainable improvements in care and access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dysmenorrhea Treatment Market, by Treatment Type

  • 8.1. Non Pharmacological
    • 8.1.1. Acupuncture Therapy
    • 8.1.2. Dietary Supplements
      • 8.1.2.1. Herbal Extracts
      • 8.1.2.2. Omega 3 Supplements
      • 8.1.2.3. Vitamin Supplements
    • 8.1.3. Exercise Therapy
    • 8.1.4. Heat Therapy
  • 8.2. Pharmacological

9. Dysmenorrhea Treatment Market, by Drug Class

  • 9.1. Hormonal Contraceptives
  • 9.2. Nsaids

10. Dysmenorrhea Treatment Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Topical

11. Dysmenorrhea Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Dysmenorrhea Treatment Market, by Application

  • 12.1. Primary Dysmenorrhea
  • 12.2. Secondary Dysmenorrhea

13. Dysmenorrhea Treatment Market, by End User

  • 13.1. Clinics
  • 13.2. Home Care
  • 13.3. Hospitals
  • 13.4. Specialty Centers
    • 13.4.1. Fitness Centers
    • 13.4.2. Gynecological Clinics

14. Dysmenorrhea Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Dysmenorrhea Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Dysmenorrhea Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Dysmenorrhea Treatment Market

18. China Dysmenorrhea Treatment Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. AbbVie Inc.
  • 19.7. Astellas Pharma
  • 19.8. AstraZeneca
  • 19.9. Bayer AG
  • 19.10. Boehringer Ingelheim
  • 19.11. Cipla Inc.
  • 19.12. Dr. Reddy's Laboratories Ltd.
  • 19.13. GlaxoSmithKline plc (GSK)
  • 19.14. Haleon Plc
  • 19.15. Himalaya Wellness Co.
  • 19.16. Johnson & Johnson
  • 19.17. Lupin
  • 19.18. Novartis International AG
  • 19.19. Perrigo Company plc
  • 19.20. Pfizer Inc.
  • 19.21. Reckitt Benckiser Group PLC.
  • 19.22. Sanofi S.A.
  • 19.23. Sun Pharmaceutical Industries Ltd.
  • 19.24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DYSMENORRHEA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DYSMENORRHEA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ACUPUNCTURE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ACUPUNCTURE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ACUPUNCTURE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY OMEGA 3 SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY OMEGA 3 SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY OMEGA 3 SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HEAT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HEAT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HEAT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HORMONAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HORMONAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HORMONAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PRIMARY DYSMENORRHEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PRIMARY DYSMENORRHEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PRIMARY DYSMENORRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SECONDARY DYSMENORRHEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SECONDARY DYSMENORRHEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SECONDARY DYSMENORRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY FITNESS CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY FITNESS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY FITNESS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY GYNECOLOGICAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY GYNECOLOGICAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY GYNECOLOGICAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 181. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. GCC DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 208. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 211. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. G7 DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 218. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 221. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 222. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. NATO DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)